Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TROXYCA ER vs ADDERALL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TROXYCA ER is a fixed-dose combination of oxycodone hydrochloride, a mu-opioid receptor agonist, and naltrexone hydrochloride, a mu-opioid receptor antagonist. Naltrexone is sequestered in the core of the tablet and is not released if taken as directed; however, if crushed or chewed, naltrexone is released and blocks the effects of oxycodone, reducing abuse potential.
Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Attention deficit hyperactivity disorder (ADHD),Narcolepsy
One capsule orally once daily at approximately the same time each day. The dosage strength should be individualized based on prior opioid use and tolerance. For opioid-naive patients, initiate with the lowest available strength (e.g., 60 mg/3.2 mg). Titrate no more frequently than every 3-7 days as needed.
10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.
Tramadol: 5–6 hours; acetaminophen: 2–3 hours. Clinical context: Steady-state reached in ~1-2 days.
Mean terminal half-life: d-amphetamine 10 h, l-amphetamine 13 h (range 9-14 h); for ADDERALL 15 (3:1 mix), effective half-life ~11 h; clinical context: dosing interval typically QD-BID.
Oxycodone is extensively metabolized in the liver via CYP3A4 and CYP2D6; naltrexone is metabolized primarily to 6β-naltrexol by dihydrodiol dehydrogenase.
Amphetamine is metabolized primarily by hepatic CYP2D6 and to a lesser extent by CYP2C19 and CYP2C9, with some minor pathways involving dopamine beta-hydroxylase.
Renal: ~70% as unchanged drug and metabolites (tramadol, acetaminophen), biliary/fecal: ~30%.
Primarily renal (90% as unchanged drug and metabolites; ~30% unchanged, 40% as 4-hydroxyamphetamine and conjugates, 20% as other metabolites); minimal biliary/fecal elimination (<3%).
Tramadol: ~20% bound primarily to albumin; acetaminophen: negligible binding (<5%).
~16-20%; primarily binds to albumin, with minor binding to alpha-1-acid glycoprotein.
Tramadol: ~2.6–3.0 L/kg; acetaminophen: ~0.9–1.0 L/kg. Indicates extensive tissue distribution for tramadol.
Vd: 3.0-4.5 L/kg (range 2.6-5.6); indicates extensive tissue distribution, including brain, with accumulation in kidneys and liver.
Oral: ~75% (tramadol); acetaminophen: ~88%.
Oral: ~76% (range 64-95%) for mixed amphetamine salts; bioavailability reduced by acidic gastric p H and increased with food (Tmax delayed but AUC unchanged).
For GFR 30-89 m L/min: No adjustment recommended. For GFR 15-29 m L/min: Initiate with 60 mg/3.2 mg once daily and titrate cautiously; monitor for respiratory depression. For GFR <15 m L/min: Not recommended due to accumulation of metabolites.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: contraindicated.
For Child-Pugh Class A (mild impairment): No adjustment. For Child-Pugh Class B (moderate impairment): Initiate with 60 mg/3.2 mg once daily and titrate cautiously. For Child-Pugh Class C (severe impairment): Not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not approved for use in pediatric patients (safety and efficacy not established).
Weight-based: <50 kg: 2.5-5 mg once daily; 50-100 kg: 5-10 mg once daily; >100 kg: adult dosing.
Initiate with the lowest available strength (60 mg/3.2 mg) once daily and titrate cautiously due to increased sensitivity and risk of respiratory depression; consider renal function decline.
Start at 2.5-5 mg once daily; increase slowly due to increased sensitivity and cardiovascular risk.
WARNING: ADDICTION, ABUSE AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
WARNING: ABUSE AND DEPENDENCE. CNS stimulants, including Adderall, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence throughout therapy.
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion (especially in children),Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Interaction with alcohol,Risk of severe hypotension,Risk of seizures in patients with seizure disorders,Avoid use in patients with gastrointestinal obstruction
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Blood pressure and heart rate increases,Psychiatric adverse events (exacerbation of pre-existing psychosis, manic episodes, aggressive behavior),Seizures (may lower seizure threshold),Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome risk, especially with concomitant serotonergic drugs,Long-term growth suppression in children
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction (including paralytic ileus),Concurrent use of monoamine oxidase inhibitors (MAOIs) or use within 14 days of such therapy,Hypersensitivity to oxycodone, naltrexone, or any component of the product
Hypersensitivity to amphetamine or other components,Concurrent use or within 14 days of MAOIs (risk of hypertensive crisis),Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease (symptomatic, moderate to severe hypertension, advanced arteriosclerosis, structural cardiac abnormalities)
Avoid alcohol and alcoholic beverages. No specific food restrictions; however, a high-fat meal may slightly increase oxycodone absorption, but no dose adjustment needed.
Avoid high-fat meals close to dosing as they may delay absorption. Acidic foods (e.g., citrus, cola, vitamin C) can decrease absorption; take with non-acidic fluids. Avoid alcohol and caffeine-containing products.
First trimester: No adequate human data; animal studies show no teratogenicity at exposures up to 10 times MRHD. Second/third trimester: Prolonged use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid chronic use.
First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/third trimesters: Risk of fetal growth restriction, preterm delivery, neonatal withdrawal (irritability, feeding problems), and persistent pulmonary hypertension.
M/P ratio unknown. Oxycodone and naltrexone enter breast milk in low amounts; monitor infant for sedation and respiratory depression. Benefits may outweigh risks with short-term use.
Present in breast milk; M/P ratio approximately 2.5-7.5. Potential for infant stimulation, insomnia, reduced weight gain. Caution recommended; consider delaying breastfeeding until 1-2 hours after dose.
No specific dose adjustments recommended; pharmacokinetic changes (e.g., increased clearance, decreased protein binding) may necessitate careful titration. Use lowest effective dose for shortest duration.
Pregnancy reduces amphetamine plasma concentrations by 15-50% during second/third trimesters due to increased clearance. Dose may need upward titration to maintain clinical effect, with careful monitoring for adverse effects.
TROXYCA ER is a fixed-dose combination of oxycodone and naltrexone designed for abuse deterrence. The naltrexone is sequestered and released only if the tablet is crushed, precipitating withdrawal in opioid-dependent individuals. It is not indicated for PRN use; only for around-the-clock management of severe chronic pain. Avoid in patients with opioid dependence due to risk of precipitated withdrawal. Do not administer with alcohol or other CNS depressants due to additive effects. Monitor for respiratory depression, especially in elderly or debilitated patients.
Adderall 15 mg (amphetamine/dextroamphetamine) is an immediate-release formulation; onset 30-60 min, duration 4-6 hours. Avoid afternoon doses to prevent insomnia. Monitor for hypertension, tachycardia, and growth suppression in children. Consider drug holidays to assess need and reduce tolerance. Do not use with MAOIs or within 14 days of MAOI therapy. Risk of abuse and dependence; screen for substance use history. Use with caution in patients with pre-existing cardiovascular disease or psychiatric disorders.
Take exactly as prescribed; do not crush, chew, or dissolve tablets.,This medication contains an opioid that can be habit-forming; use only for your pain and do not share with others.,Do not drink alcohol while taking this medication; it can increase the risk of severe drowsiness and respiratory depression.,Common side effects include constipation, nausea, dizziness, and drowsiness; report severe or persistent symptoms.,Store safely out of reach of children and dispose of unused tablets via a take-back program or flushing (per FDA guidelines).,Do not stop abruptly without talking to your doctor to avoid withdrawal symptoms.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Take the first dose in the morning; if prescribed a second dose, take it by early afternoon to avoid sleep problems.,Swallow tablet whole; do not crush or chew.,Avoid alcohol and caffeine; may increase side effects like nervousness and rapid heartbeat.,Report chest pain, palpitations, shortness of breath, or fainting immediately.,Inform your doctor of all medications, including over-the-counter and herbal products, especially antidepressants.,May cause weight loss; monitor growth in children.,Can impair ability to drive or operate machinery until you know how it affects you.,Store at room temperature away from moisture and heat.,Do not abruptly stop; taper under medical supervision to avoid withdrawal.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TROXYCA ER vs ADDERALL 15, answered by our medical review team.
TROXYCA ER is a Opioid Analgesic (with abuse-deterrent properties) that works by TROXYCA ER is a fixed-dose combination of oxycodone hydrochloride, a mu-opioid receptor agonist, and naltrexone hydrochloride, a mu-opioid receptor antagonist. Naltrexone is sequestered in the core of the tablet and is not released if taken as directed; however, if crushed or chewed, naltrexone is released and blocks the effects of oxycodone, reducing abuse potential.. ADDERALL 15 is a CNS Stimulant that works by Adderall 15 is a combination of amphetamine and dextroamphetamine, which increase synaptic concentrations of norepinephrine and dopamine by inhibiting their reuptake and promoting their release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TROXYCA ER and ADDERALL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TROXYCA ER is: One capsule orally once daily at approximately the same time each day. The dosage strength should be individualized based on prior opioid use and tolerance. For opioid-naive patients, initiate with the lowest available strength (e.g., 60 mg/3.2 mg). Titrate no more frequently than every 3-7 days as needed.. The standard adult dose of ADDERALL 15 is: 10-20 mg orally once daily in the morning; may increase by 5-10 mg weekly; maximum 40 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TROXYCA ER and ADDERALL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TROXYCA ER is classified as Category C. First trimester: No adequate human data; animal studies show no teratogenicity at exposures up to 10 times MRHD. Second/third trimester: Prolonged use may cause neonatal opioid wit. ADDERALL 15 is classified as Category C. First trimester: Possible increased risk of congenital malformations (cardiac, oral clefts) based on limited human data; animal studies show dose-dependent teratogenicity. Second/t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.